

Prescribing and Formulary Panel

Minutes of the meeting held on September 7th 2021 via TEAMS

Present

Geraldine O’Riordan, Prescribing Advisor and Chair (GOR)

Janine Clarke, Pharmacy Manager, HSC (JC)

Nikki Brink, States-Employed Doctors and DPH (NB)

Paul Williams, Island Health (PH)

Beverley Hall, Chief Pharmacist States of Guernsey (BH)

Apologies

Tom Saunders, Medical Specialist Group (HD), Mike McCarthy, Healthcare Group (MMC)

Absent

Hamish Duncan, Medical Specialist Group (HD), Douglas Wilson, Queens Road Medical Practice (DW) Peter Gomes, Medical Specialist Group (PG)

1: Minutes

The draft minutes of the August 2021 meeting were approved.

2. New Drugs

The following products were considered

1. Emicizumab reconsideration

Discussion to redacted for patient confidentiality reasons.

After a discussion it was agreed unanimously to recommend emicizumab for approval subject to NHS prescribing criteria and for PEH Pharmacy dispensing only.

Action: GOR/JC

2. **Pregabalin** : discussion deferred at the request of MMC

Action: GOR

3. **Biktavry^R**

This product has been requested by NB following an MDT recommendation. It is a combination of bicitgravir/emtricitabine/tenofovir alafemide and is licensed for use in the treatment of adults infected with human immunodeficiency virus 1 (HIV-1) in certain circumstances. The dose is one tablet once daily and it is recommended for NHS patients in England (by NHSE in certain circumstances), in Scotland and in Wales (the latter in limited circumstances), if the company sells it at the NHS discounted price or lower. GOR said that despite multiple requests to the company, no agreement has been reached to access the product at the NHS price or lower.

Actions: GOR

4. New NICE TA drugs

It was noted that the ICER per QALY for TA 668 is between £30K and £40K, but approval is being brought forward from year 2 to year 1 because one patient requires it urgently.

C. Cost-neutral /minor amendments

The following products were considered and recommended

- Ursodeoxycholic acid 500mg tablets : a new cost-neutral strength of a drug already available.
- Sertraline 100mg per 5 ml oral suspension: required for a patient already on sertraline with motor neurone disease who is unable to swallow tablets.
- Tacrolimus 200 microgram granules in sachets: required for a child who is unable to swallow tacrolimus tablets.

4: Date of next meeting: Tuesday October 5th 2021